AstraZeneca PLC (AZN)

NASDAQ: AZN · IEX Real-Time Price · USD
68.93
-0.52 (-0.75%)
At close: Apr 12, 2024, 4:00 PM
68.83
-0.10 (-0.15%)
Pre-market: Apr 15, 2024, 4:10 AM EDT
-0.75%
Market Cap 213.67B
Revenue (ttm) 45.81B
Net Income (ttm) 5.96B
Shares Out 3.10B
EPS (ttm) 1.91
PE Ratio 36.28
Forward PE 16.31
Dividend $1.45 (2.10%)
Ex-Dividend Date Feb 22, 2024
Volume 7,100,859
Open 69.66
Previous Close 69.45
Day's Range 68.60 - 69.82
52-Week Range 60.47 - 76.56
Beta 0.19
Analysts Buy
Price Target 81.67 (+18.48%)
Earnings Date Apr 25, 2024

About AZN

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus... [Read more]

Sector Healthcare
IPO Date May 12, 1993
Employees 89,900
Stock Exchange NASDAQ
Ticker Symbol AZN
Full Company Profile

Financial Performance

In 2023, AstraZeneca's revenue was $45.81 billion, an increase of 3.29% compared to the previous year's $44.35 billion. Earnings were $5.96 billion, an increase of 81.11%.

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for AZN stock is "Buy." The 12-month stock price forecast is $81.67, which is an increase of 18.48% from the latest price.

Price Target
$81.67
(18.48% upside)
Analyst Consensus: Buy
Stock Forecasts

News

No Evidence Linking Ozempic And Suicidal Thoughts, EU Says

There is no evidence linking diabetes and weight loss drugs like Ozempic and Wegovy to an increase in suicidal thoughts, the European Union's drug regulator said Friday, the latest findings casting do...

Other symbols: LLYNVO
2 days ago - Forbes

FASENRA approved for treatment of children aged 6 to 11 with severe asthma

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's FASENRA® (benralizumab) is now approved by the US Food and Drug Administration (FDA) for add-on maintenance treatment for patients with severe asthma a...

3 days ago - Business Wire

AstraZeneca unveils dividend hike ahead of CEO pay vote at AGM

AstraZeneca said on Thursday it intends to increase annual dividend for 2024 by 7% to $3.10 per share, betting on strong performance and cash generation on the back of its blockbuster drugs and severa...

4 days ago - Reuters

Eli Lilly's and AstraZeneca's Former Head of Research Dr. Jan Lundberg Invests in AlzeCure and is Proposed for Election to its Board

STOCKHOLM, SWEDEN / ACCESSWIRE / April 10, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB ("AlzeCure" or "the Company"), a pharmaceutical company that develops candidate drugs for CNS...

Other symbols: LLY
5 days ago - Accesswire

Meet Europe's Mag 18. Novo Nordisk Stock, ASML, and Others Can Rival the Mag Seven.

The Mag Seven stocks have powered gains in the U.S. market. Now, the hunt is on for an equivalent group of outperformers elsewhere.

5 days ago - Barrons

ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2+ Solid Tumors.

9 days ago - Business Wire

ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumors

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Daiichi Sankyo's ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved in the US for the treatment of adult patients with unresectable or meta...

9 days ago - Business Wire

US FDA approves Daiichi, AstraZeneca drug for treatment of solid tumors

The U.S. Food and Drug Administration on Friday gave accelerated approval for the expanded use of Daiichi Sankyo and AstraZeneca's drug to treat patients with a type of solid tumor.

9 days ago - Reuters

AstraZeneca's Imfinzi shows promise in treating aggressive lung cancer

Drugmaker AstraZeneca said on Friday its blockbuster cancer drug Imfinzi showed "significant and clinically meaningful" improvement in the primary goals of a late-stage trial designed for an aggressiv...

10 days ago - Reuters

Healthy Returns: Weight loss, diabetes drug ad spending tops $1 billion

Drugmakers spent big on ads for weight loss and diabetes drugs such as Wegovy and Ozempic. Meanwhile, the FDA approved the first AI diagnostic tool for sepsis.

Other symbols: LLYNVO
11 days ago - CNBC

Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Daiichi Sankyo's Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the US for the treatment of adult pat...

12 days ago - Business Wire

Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) and AstraZeneca's (LSE/STO/Nasdaq: AZN) Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been acce...

13 days ago - Business Wire

VOYDEYA™ approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular hemolysis in adults with the rare disease PNH

WILMINGTON, Del.--(BUSINESS WIRE)--VOYDEYA™ (danicopan) has been approved in the US as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with par...

13 days ago - Business Wire

AstraZeneca CEO Soriot on Pharmaceuticals in China

AstraZeneca CEO Pascal Soriot discusses the drugmaker's business strategy in China, the US “BIOSECURE Act,” and future deals and partnerships in China. He speaks with Stephen Engle on the sidelines of...

19 days ago - Bloomberg Markets and Finance

AstraZeneca: Fusion acquisition will be a cost effective-investment that can improve cancer outcomes

Dr. Susan Galbraith, executive vice-president of oncology and R&D at AstraZeneca, discusses the healthcare giant's $2.4bn acquisition of Fusion Pharmaceuticals.

26 days ago - CNBC International TV

AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation rad...

26 days ago - Business Wire

AstraZeneca to buy Fusion Pharmaceuticals for up to $2.4 billion

AstraZeneca is buying Fusion Pharmaceuticals for $2.4 billion as the London-listed group looks to build its presence in cutting-edge cancer treatments.

Other symbols: FUSN
27 days ago - Market Watch

AstraZeneca to buy Fusion Pharma for $2 billion in cash

AstraZeneca said on Tuesday it will buy clinical-stage biopharmaceutical company Fusion Pharmaceuticals Inc for about $2 billion in cash to boost its oncology portfolio.

Other symbols: FUSN
27 days ago - Reuters

AstraZeneca to cap US out-of-pocket costs for inhalers to $35

AstraZeneca said on Monday it would cap out-of-pocket costs for its inhaled respiratory products for chronic lung disease and asthma to $35 per month, starting June, in the United States.

27 days ago - Reuters

AstraZeneca caps patient out-of-pocket costs at $35 per month for its US inhaled respiratory portfolio

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca announced it will expand the savings programs for its entire US inhaled respiratory portfolio, helping eligible patients pay no more than $35 per month f...

27 days ago - Business Wire

AstraZeneca To Buy Amolyt Pharma for $1.05B To Expand Rare Disease Pipeline

AstraZeneca PLC (AZN) plans to acquire biotech firm Amolyt Pharma for $1.05 billion in cash, the drugmaker said Thursday, boosting its pipeline of drugs to treat rare diseases.

4 weeks ago - Investopedia

Sofinnova Partners Portfolio Company Amolyt Pharma to be Acquired by AstraZeneca

PARIS--(BUSINESS WIRE)-- #VC--Sofinnova Partners announced that its portfolio company, Amolyt Pharma, has entered into a definitive agreement with AstraZeneca for its acquisition.

4 weeks ago - Business Wire

AstraZeneca strikes $1 billion deal for rare-disease drug maker

AstraZeneca on Thursday struck a $1 billion deal to buy a maker of drug for rare diseases, further building out the capabilities it acquired in the 2021 deal for Alexion Pharmaceuticals.

4 weeks ago - Market Watch

Amolyt Pharma Enters into Definitive Agreement to be Acquired by AstraZeneca

AstraZeneca will acquire Amolyt Pharma for up to $1.05 billion in total consideration The transaction is expected to close in the third quarter of 2024 LYON, France and CAMBRIDGE, Mass., March 14, 202...

4 weeks ago - GlobeNewsWire

AstraZeneca to buy Amolyt Pharma for $1.05 bln to boost rare diseases portfolio

Drugmaker AstraZeneca said on Thursday it will acquire rare endocrine diseases-focused firm Amolyt Pharma for $1.05 billion in cash, in a bid to boost its rare diseases portfolio.

4 weeks ago - Reuters